Neurology Plan definition

Neurology Plan means any of the following plans: (i) the Core Research Plan, (ii) the Neurological Disease Research Plan, (iii) any ASO Development Candidate Identification Plans, or (iv) any Initial Development Plans.
Sample 1Sample 2Sample 3
Neurology Plan means any of the following plans: (a) the Core Research Plan, (b) the Neurological Disease Research Plan, including, for clarity, any final Target Sanction Plan, (c) any Development Candidate Identification Plans, (d) the Toxicology Strategy or (e) any Integrated Product Plans.
Sample 1Sample 2

Examples of Neurology Plan in a sentence

  • The Contracting Party will not be responsible for any activities under a Neurology Plan that it is unable to perform as a result of the other Party’s refusal to consent to the terms of any agreement with any such academic or non-profit institution.

  • To the extent any such Research or Development activities are allocated to Biogen in accordance with the preceding sentence, such activities will be Biogen Activities and Biogen will use its Commercially Reasonable Efforts to conduct such Research or Development activities in accordance with the applicable Neurology Plan.

  • Notwithstanding the foregoing, no later than [***] days prior to the anticipated date of finalization of the applicable Neurology Plan, the Party preparing such Neurology Plan shall provide the Neurology JRC or Neurology JDC and the JPC with a list of the academic or non-profit institutions with which such Party proposes to conduct activities under such Neurology Plan, and the nature and scope of such activities.

  • The [***] may provide the Neurology JRC or Neurology JDC, as applicable, with recommendations on the [***] considerations arising from such proposed academic or non-profit collaborations, and the Parties, through the Neurology JRC or Neurology JDC, as applicable, shall consider in good faith such recommendations prior to finalizing the Neurology Plan and such collaborations.

  • Prior to the License Effective Date with respect to a Collaboration Program, (a) Biogen will use Commercially Reasonable Efforts to conduct any Biogen Activities and (b) Ionis will use Commercially Reasonable Efforts to conduct any Ionis Activities, in each case ((a) and (b)), on the timelines set forth in the applicable Neurology Plan.

  • For ALS Collaboration Programs, Isis will supply API (on its own or through a CMO approved by Biogen Idec) and Clinical Supplies to support the Research and Development activities under each Neurology Plan through the first Phase 2 Trial, and such supply will be at Biogen Idec’s expense using the mechanism set forth in S ection 1.14.

  • For ALS Collaboration Programs, Isis will supply API (on its own or through a CMO approved by Biogen Idec) and Clinical Supplies to support the Research and Development activities under each Neurology Plan through the first Phase 2 Trial, and such supply will be at Biogen Idec’s expense using the mechanism set forth in Section 1.14.

  • Each Party (the “Contracting Party”) may engage one or moreacademic or non-profit institutions to conduct work under any Neurology Plan or on any High Interest Target or Collaboration Target.

  • Each Party (the “Contracting Party”) may engage one or more academic or non-profit institutions to conduct work under any Neurology Plan or on any High Interest Target or Collaboration Target.

  • Prior to Option exercise, Biogen Idec will use Commercially Reasonable Efforts to conduct (i) any Biogen Idec Activities on the timeline set forth in the applicable Neurology Plan, and (ii) except as provided under S ection 1.10.2(c)(ii), for each ALS Collaboration Program all activities under each Initial Development Plan on the timeline set forth in the applicable Initial Development Plan.

Related to Neurology Plan

  • Commercialization Plan has the meaning set forth in Section 6.2.

  • Flexi Plan means any individual indemnity hospital insurance plan under the VHIS framework with enhancement(s) to any or all of the protections or terms and benefits that the Standard Plan provides to the Policy Holder and the Insured Person, subject to certification by the Government. Such plan shall not contain terms and benefits which are less favourable than those in the Standard Plan, save for the exception as may be approved by the Government from time to time.

  • Development Plan has the meaning set forth in Section 3.2.

  • Program Plan means the tobacco settlement program plan dated February 14, 2001, including exhibits to the program plan, submitted by the authority to the legislative council and the executive council, to provide the state with a secure and stable source of funding for the purposes designated by section 12E.3A and other provisions of this chapter.

  • Joint Commercialization Committee or “JCC” has the meaning set forth in Section 2.1(a).

  • Research Plan shall have the meaning set forth in Section 2.1.

  • Development Plans has the meaning set forth in Section 3.2.

  • Home study means the assessment process used for the purpose of determining the ability of an applicant to care for a child in need of foster care placement.

  • Development Program means the implementation of the development plan.

  • Supply Plan has the meaning set forth in the CAISO Tariff.

  • Basic health plan model plan means a health plan as required in RCW 70.47.060(2)(e).

  • Pivotal Study means (a) a Phase 3 Study that is intended by Celgene to be submitted (together with any other registration trials that are prospectively planned when such Phase 3 Study is initiated) for Regulatory Approval in the U.S. or the EU, or (b) any other clinical study that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which clinical study is a registration trial intended to be sufficient for filing an application for a Regulatory Approval for the Licensed Product in the U.S. or another country or some or all of an extra-national territory, solely as evidenced by the acceptance for filing for a Regulatory Approval for such product after completion of such study.

  • Integrated Development Plan means a plan formulated and approved as envisaged in Section 25 of the Municipal Systems Act 2000, as amended.

  • EHC plan means an Education, Health and Care plan made under sections 37(2) of the Children and Families Act 2014.

  • Redevelopment Plan means the “Lincoln Center Redevelopment Plan” passed, adopted and approved by the City pursuant to the Resolution, and shall include any amendment of said Redevelopment Plan heretofore or hereafter made by the City pursuant to law.

  • Safety Plan means a written document that has procedures, requirements, or standards related to safety which the pool staff shall follow. The safety plan shall include training and emergency response procedures.

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • POC (Proof of Concept) means testing the Software for evaluation purposes.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Indicators of student progress and growth means the results of assessment(s) of students as defined in N.J.A.C. 6A:8, Standards and Assessment.

  • Marketing Plan means a plan or system concerning a material aspect of conducting business. Indicia of a marketing plan include any of the following:

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • System Impact Study means an assessment by the Transmission Provider of (i) the adequacy of the Transmission System to accommodate a Completed Application, an Interconnection Request or an Upgrade Request, (ii) whether any additional costs may be incurred in order to provide such transmission service or to accommodate an Interconnection Request, and (iii) with respect to an Interconnection Request, an estimated date that an Interconnection Customer’s Customer Facility can be interconnected with the Transmission System and an estimate of the Interconnection Customer’s cost responsibility for the interconnection; and (iv) with respect to an Upgrade Request, the estimated cost of the requested system upgrades or expansion, or of the cost of the system upgrades or expansion, necessary to provide the requested incremental rights. System Protection Facilities: “System Protection Facilities” shall refer to the equipment required to protect (i) the Transmission System, other delivery systems and/or other generating systems connected to the Transmission System from faults or other electrical disturbance occurring at or on the Customer Facility, and (ii) the Customer Facility from faults or other electrical system disturbance occurring on the Transmission System or on other delivery systems and/or other generating systems to which the Transmission System is directly or indirectly connected. System Protection Facilities shall include such protective and regulating devices as are identified in the Applicable Technical Requirements and Standards or that are required by Applicable Laws and Regulations or other Applicable Standards, or as are otherwise necessary to protect personnel and equipment and to minimize deleterious effects to the Transmission System arising from the Customer Facility. Transmission Facilities:

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.